Kamisu, Japan

Hirofumi Kuroda

USPTO Granted Patents = 6 


Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 39(Granted Patents)


Location History:

  • Ibaraki, JP (2001)
  • Kamisu, JP (2019 - 2023)

Company Filing History:


Years Active: 2001-2023

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Hirofumi Kuroda: Innovator in Pharmaceutical Compounds

Introduction

Hirofumi Kuroda is a notable inventor based in Kamisu, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds and their applications. With a total of 6 patents to his name, Kuroda's work has the potential to impact drug development and therapeutic solutions.

Latest Patents

Kuroda's latest patents include innovative compounds that demonstrate promising pharmaceutical applications. One of his notable inventions is the "Salts of compounds and crystals thereof," which provides crystals of a complex compound with potential use as a drug substance. This compound, identified as (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34λ,39λ-diphosphaoctacyclo[28.6.4.10.10000]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)), showcases its potential as a drug substance in pharmaceuticals. Another significant patent is for a "High-purity quinoline derivative and method for manufacturing same," which details a compound with a specific purity level, enhancing its applicability in various pharmaceutical formulations.

Career Highlights

Throughout his career, Kuroda has worked with prominent companies in the pharmaceutical industry. He has been associated with Eisai R&D Management Co., Ltd. and Eisai Company, Limited, where he has contributed to research and development efforts. His work has focused on creating innovative solutions that address medical needs and improve patient outcomes.

Collaborations

Kuroda has collaborated with esteemed colleagues in his field, including Taiju Nakamura and Taichi Abe. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Hirofumi Kuroda's contributions to the

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…